Ten frontline pharmacy- and clinic-adjacent retail supervisors — the people who watch pharma reps work the counter every day — on how field-sales behaviour is changing: post-COVID access restrictions, the shift to specialty drugs, digital and AI tooling, and headcount. This is the view from the counter, not the rep's own account.
The drop-in detailer is being replaced by an access-and-reimbursement operator. Reweight field coverage toward independents and elective / cash-pay specialties; the hospital-system wall is structural, and scarce in-person time only pays where it reliably outperforms digital.
Every supervisor agrees access tightened. They split hard on how absolute the wall is: in large urban systems it is badge, portal and appointment or nothing; in rural markets a known rep who solves operational pain still walks in the door.
From Q2 of 7: "How has physician access changed in your territory? … which specialties or practice types have become nearly impossible to get in front of, and which are actually more accessible now?" · Camps analyst-classified from the study's segment analysis — see methodology.
Hover any respondent to read what they observe, as reported in the study analysis. Colour follows the three camps above.
The drop-in rep is dead. Access is badge, portal, appointment — or nothing. Hospital- and system-owned sites are the hardest wall.
Out here, a known rep who solves prior-auth pain still walks in. Independents stay reachable when reps bring real logistics help.
The two markets agree on the mechanism and split on the wall: digital carries volume everywhere (~80% of touches), but scarce in-person time reliably outperforms for prescribing impact — and only in independents and elective / cash-pay specialties is that in-person time still winnable.
One row per supervisor, one column per priority the study ties them to. Column totals rank what actually earns a rep time at the counter — operational relief, not detailing polish.
| Supervisor | Access & credentialing discipline |
Operational relief over promo |
In-person reserved for impact |
Friction-only AI (no NBA dashboards) |
Bilingual + micro-training |
|---|---|---|---|---|---|
| Tammy Rosalesurban · San Diego | |||||
| John Carrollurban · New York | |||||
| Casey Zimmermanurban · New York | |||||
| Elizabeth Kapoorurban · Alameda | |||||
| Breahna Amaralrural · NC | |||||
| Fidel Garvinrural · TN | |||||
| Ronnie Caravantesrural · TX | |||||
| Anthony Hillmanrural · NE | |||||
| Brittany Lungrural · MI | |||||
| Christina Schneidersmall-city · Knoxville | |||||
| named by | 3/10 | 5/10 | 4/10 | 5/10 | 5/10 |
The structural direction is agreed everywhere; the fights are about the urban wall, AI tooling, and the 2028 driver. Splits are analyst-classified from the study's segment and divergence analysis.
The panel's one tooling fight. Hard-stop compliance checks and predictive queues stick because they save minutes or audit risk; next-best-action dashboards get overridden in every rush.
10 pharmacy- and clinic-adjacent retail supervisors recruited from a census-grounded synthetic population of 340,000 US residents, split across urban health systems and rural independents to capture both access realities.
Ten pharmacy- and clinic-adjacent retail supervisors — daily observers of pharma reps at the counter — describe in-person calls as materially fewer, shorter and appointment-only, with 60–95% of touches now digital and a persistent efficacy gap favouring the rare in-person visit.
What this argues for: reweight coverage to independents and elective / cash-pay specialties; reserve scarce in-person time for high-potential accounts; retrain toward access and reimbursement; prioritise AI that reduces audit friction over dashboards.
FishDog · Research without respondents · Fielded May 27, 2026 · 10 counter-side supervisors · 7 questions · 70 responses · v2.0, rebuilt 2026-07-11. Positions and demographics are from the study record; access camps are analyst-classified from the study's divergence analysis. How this report is structured.